Biofrontera

Biofrontera Profit per Employee

The Profit per Employee of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -25,580.65 EUR. In the previous year, Profit per Employee was -28,064.52 EUR — a change of -8.85% (higher).

Profit per Employee

-25,580.65EUR

YoY

-8.85%

Last updated:

Profit per Employee of Biofrontera is 2025 -25,580.65 EUR. Profit per Employee of Biofrontera was 2024 -28,064.52 EUR. It decreases by -8.85% higher compared to the previous year.

The Biofrontera Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-57,277.42 EUR
Jan 1, 2019
-47,470.97 EUR
Jan 1, 2020
-84,019.35 EUR
Jan 1, 2021
243,529.03 EUR
Jan 1, 2022
-284,941.94 EUR
Jan 1, 2023
-2,380.65 EUR
Jan 1, 2024
-28,064.52 EUR
Jan 1, 2025
-25,580.65 EUR
The Biofrontera Profit per Employee history
YEARProfit per EmployeeYoY
-25,580.65EUR-8.85%
-28,064.52EUR+1,078.86%
-2,380.65EUR-99.16%
-284,941.94EUR-217.01%
243,529.03EUR-389.85%
-84,019.35EUR+76.99%
-47,470.97EUR-17.12%
-57,277.42EUR-44.86%
-103,883.87EUR+52.20%
-68,252.93EUR-5.57%
-72,280.06EUR+4.50%
-69,167.60EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Profit per Employee of Biofrontera is -25,580.65 EUR in 2025.

Profit per Employee of Biofrontera changed from -28,064.52 EUR to -25,580.65 EUR, representing a -8.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biofrontera

All Key Metrics — Biofrontera